Compare CLW & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | TNYA |
|---|---|---|
| Founded | 1926 | 2016 |
| Country | United States | United States |
| Employees | 3710 | N/A |
| Industry | Paper | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.3M | 178.5M |
| IPO Year | 2008 | 2021 |
| Metric | CLW | TNYA |
|---|---|---|
| Price | $14.86 | $0.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $23.00 | $5.33 |
| AVG Volume (30 Days) | 188.6K | ★ 5.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.16 | $1,456.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $12.46 | $0.36 |
| 52 Week High | $30.96 | $2.35 |
| Indicator | CLW | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 45.30 |
| Support Level | $12.46 | $0.66 |
| Resistance Level | $18.85 | $0.70 |
| Average True Range (ATR) | 0.67 | 0.06 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 91.95 | 25.73 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.